TheraRadar
Data updated: May 26, 2026

ACANYA (benzoyl peroxide)

Dermatology Approved 2008-10-23

ACANYA is indicated for the treatment of Acne Vulgaris.

Source: FDA Label • BAUSCH
2
Indications
--
Phase 3 Trials
17
Years on Market

Details

Status
Prescription
First Approved
2008-10-23
Patent Cliff
2029

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
GEL

Companies

ACANYA Approval History

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
13 FDA actions from 2008 to 2020 · 1 indication expansions
Feb 2020 SUPPL
Label · Labeling
Mar 2016 SUPPL
Mfg · Manufacturing (CMC)
Nov 2015 SUPPL
Mfg · Manufacturing (CMC)

What ACANYA Treats

1 indications

ACANYA is approved for 1 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acne Vulgaris
Source: FDA Label

ACANYA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ACANYA

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACZONE
DAPSONE
1 shared
ALMIRALL
Shared indications:
ADAPALENE AND BENZOYL PEROXIDE
ADAPALENE
1 shared
PADAGIS ISRAEL
Shared indications:
AKLIEF
TRIFAROTENE
1 shared
GALDERMA LABS LP
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT05536882 IRB# 14663 Ph 3 withdrawn MC RCT - BPO vs Adapalene
NCT04548349 results posted 2020P000595 Ph 4 completed Profiling the Skin Microbiome in Response to Altreno in Acne Patients
NCT02589405 Benzac results posted RD.03.SPR.105041 Ph 4 completed Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ACANYA FDA Label Details

Indications & Usage

FDA Label (PDF)

ACANYA is indicated for the treatment of Acne Vulgaris.

View full patent landscape →
9 OB patents · 1 families · 51 international docs across 15 countries

ACANYA Patents & Exclusivity

Latest Patent: Aug 2029

Patents (9 active)

US8288434 Expires Aug 5, 2029
US9561208 Expires Jun 3, 2029
US10220049 Expires Jun 3, 2029
US9504704 Expires Jun 3, 2029
US8895070 Expires Jun 3, 2029
US10137142 Expires Jun 3, 2029
US10624918 Expires Jun 3, 2029
US8663699 Expires Jun 3, 2029
US9078870 Expires Jun 3, 2029
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for ACANYA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2029
  • 19 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 20 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.